Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cachexia

Cachexia

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cachexia

15 trials tracked for Cachexia: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 641 citations.

15Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 3 Phase 2 7 Phase 1 3 Other / NA 2
  1. Phase 3 Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1) Completed · 641 cited
  2. Phase 3 Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2) Completed · 640 cited
  3. Phase 3 Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3) Completed · 182 cited
  4. Phase 2 Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss Completed
  5. Phase 2 Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD) Completed
  6. Phase 2 Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 Completed
Show 9 more trials
  1. Phase 2 Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas Completed
  2. Phase 2 SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD) Completed
  3. Phase 2 Regimen for the Treatment of Cachexia in Subjects With NSCLC Completed
  4. Phase 2 Study of GTx-024 on Muscle Wasting (Cachexia) Cancer. Completed
  5. Phase 1 Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia Completed
  6. Phase 1 Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. Completed
  7. Phase 1 Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma Completed
  8. N/A Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer. Completed
  9. N/A Electronic-health Application To Measure Outcomes REmotely Clinical Trial Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Cachexia: what the trials found

Anamorelin HCl has demonstrated significant improvements in lean body mass and A/CS domain scores in patients with cachexia [1, 2]. Specifically, trials showed a change in lean body mass of 0.99 and 0.65 respectively (p<0.0001) and A/CS domain score improvements of 4.12 and 3.48 (p=0.0004; p=0.0016) [1, 2]. One study also reported a change in A/CS domain scores of 4.46 vs 3.24 3.

In early-phase studies for PF-06946860, patients showed changes in appetite scores at week 4 (2.45; 1.84) and across multiple weeks (ranging from 0.99 to 2.30) 11. Fatigue scores were also recorded over a 6-week period following administration 11.

Recent results — preliminary, needs further review

  • * Ponsegromab showed no significant change in physical activity or mean activity level during maximum 6 minutes at week 12 (p=0.8260; p=0.5762) 4. * SUN11031 was associated with changes in lean body mass of 37.85 to 40.39 across various time points in patients with COPD-associated cachexia 5. * BYM338 showed a 4.97% increase in total lean body mass (LBM) via DXA at week 8 compared to 2.41% for placebo 8. * Placebo Testosterone was associated with changes in total lean body mass of -3.31 vs 1.42 and improvements in peak isometric leg strength 13. * In-person nutritional counseling by a registered dietitian resulted in estimated mean weight changes of -0.1, -0.2, and -1.2 over 6 months 14.

For the clinician treating this condition

  • Anamorelin HCl is associated with statistically significant increases in lean body mass and improvements in A/CS domain scores [1, 2].
  • PF-06946860 has been shown to impact appetite scores in patients with cancer-related cachexia 11.

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Kampo medicine may support appetite and metabolic resilience in patients with sarcopenia
Nutrition & Obesity Medicine Sys. Review
Kampo medicine may support appetite and metabolic resilience in patients with sarcopenia Kampo medicines may support appetite and metabolism in muscle loss
This narrative review examines the role of Kampo medicines, including Ninjin’yoeito and Rikkunshito, for managing sarcopenia and cachexia. T…
Kampo medicines like Ninjin’yoeito show promise for managing appetite and inflammation in people with muscle loss.
Frontiers Aug 23, 2026
Narrative review on myokines in cancer, muscle atrophy, and cachexia
Oncology Sys. Review
Narrative review on myokines in cancer, muscle atrophy, and cachexia Muscle signals may help fight cancer and protect muscle in complex ways
This narrative review synthesizes evidence on myokines in cancer, muscle atrophy, and cachexia.
A review suggests muscle-derived signals could offer new ways to treat cancer, manage muscle loss, and improve patient outcomes through comb…
Frontiers Apr 21, 2026